Bahija Jallal Replaces Peter Greenleaf as MedImmune President

The Washington Post reported that biotechnology giant, MedImmune’s Peter Greenleaf has stepped down as president of the company and will be replaced by Bahija Jallal, who is currently the executive vice president of research and development.

As quoted in the market news:

The leadership change comes as MedImmune was formally designated a biologics research and development site for AstraZeneca, meaning Jallal will report directly to AstraZeneca chief executive Pascal Soriot, said company spokesman Mike O’Brien.

Click here to read the full Washington Post report.